BRAINSTORM CELL THERAPEUTICS INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 469.10 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2026-03-31
- BRAINSTORM CELL THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2023-03-31 was 44.01K shares, a 5.55% increase year-over-year.
- BRAINSTORM CELL THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2022-09-30 was 52.87K shares.
- BRAINSTORM CELL THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2022-06-30 was 6.08K shares.
- BRAINSTORM CELL THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2022-03-31 was 41.69K shares.
- BRAINSTORM CELL THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2025 was 469.10K shares, a 6923.48% increase from fiscal 2024.
- BRAINSTORM CELL THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2024 was 6.68K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 469.10K shares 10-K · filed 2026-03-31 | |||
| 2024-12-31 | 6.68K shares 10-K · filed 2026-03-31 | |||
| 2023-03-31 | 44.01K shares 10-Q · filed 2023-05-15 | |||
| 2022-09-30 | 52.87K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 58.95K shares derived: sum of 2 quarters · filed 2022-11-14 | 100.64K shares 10-Q · filed 2022-11-14 | |
| 2022-06-30 | 6.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 47.77K shares 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | 41.69K shares 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |